ER・ICUで必要な　循環器薬の知識と使い方　新装版

出版社： 総合医学社
著者：
発行日： 2015-01-31
分野： 臨床医学：一般  >  集中治療
ISBN： 9784883788842
電子書籍版： 2015-01-31 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,160 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,160 円(税込)

購入する

商品紹介

エビデンスの狭間に落ちるような疑問の方向性を特集。薬剤の選択や用量の設定、それに対する疑問やギャップをわかりやすく解説！

目次

  • ER・ICUで必要な　循環器薬の知識と使い方　新装版

    ―目次―

    I．カテコラミン
    1．果たしてノルアドレナリンはドパミンに勝るのか？
    　　　―心原性ショックのマネジメントを中心に―
    2．心不全でミルリノンが役に立つ場面はあるのか？　
    　　　ドブタミンとはどう使い分けるか？
    3．ドパミンの腎保護作用は過去のものか？
    4．時代はバゾプレッシンか？ 敗血症性ショックの治療
    5．アドレナリンとバゾプレシン， どう使い分けるか？

    II．降圧薬
    6．結局， 血圧を下げるときの第一選択薬は，
    　　　血管拡張薬なのか？　Ca拮抗薬なのか？
    7．脳血管障害で,血圧はどこまで下げるか？
    8．虚血性心疾患急性期でβ遮断薬を導入したくないワケ
    　　　（そして， なぜCa拮抗薬は好まれるのか？）　
    9．周術期短時間作用型β遮断薬の使い方?
    　　　― 日米の臨床現場での比較検討 ―

    III．抗血小板薬・抗凝固薬
    10．古典的な薬剤 ： アスピリンとヘパリンを適切に使うには
    11．新しい抗凝固薬 ― ダビガトラン と リバーロキサバン ：
    　　　　ワルファリンよりも便利かもしれないが　
    12．ヘパリンと低分子ヘパリンなど新規の抗凝固薬?
    　　　　― その使い分けの理想と現実 ―　
    13．抗血小板薬クロピドグレルの正しい使い方 ：?
    　　　そして新しい世代の抗血小板薬 prasugrel と
    　　　 ticagrelor の役割は？
    14．血栓溶解薬の使い方―脳梗塞急性期／肺血栓塞栓症急性期―
    15．出血合併症に対する考え方

    IV．急性心不全で選択する薬剤
    16． 血管拡張薬の使い方の実践?
    　　　　― そしてカルペリチドはここに入るのか？ ―?
    17．利尿薬はなくてはならないもの？　
    　　　量と切り替えのタイミングは？　
    18．いつβ ？　いつ ACE ？　
    　　　そして いつ アルドステロン拮抗薬か？

    V．抗不整脈薬
    19．レートコントロールは β か？　Ca か？?
    　　　それでもどうにもならないときは？　
    20．心房細動や粗動でリズムコントロールを行うのは
    　　　どんなとき？　そして， どんなクスリ？　
    21．エビデンスはないけれども，?
    　　　　ピルシカイニドはいろいろとよく使われる　
    22．アミオダロン ― もはや抗不整脈薬は一種類でいい？ ― 　
    23．ニフェカラントとアミオダロンは， どちらが有効か？　

    VI．その他の身近な疑問
    24．弁膜症急性期?
    　　　　― 大動脈弁狭窄症に使える薬物療法があるか？ ― 　
    25．弁膜症急性期?
    　　　　― 僧帽弁逆流症でバランスをとるための薬剤は？ ―　
    26．感染性心内膜炎での抗菌薬の基本的な考え方　
    27．心不全と輸液　
    28．腎機能悪化（WRF）を伴う心不全のマネジメントを
    　　　　どうするのか？　
    29．心疾患に相性の良い糖尿病治療薬　
    30．心疾患に相性の良い呼吸器改善薬,呼吸器疾患に
    　　　　相性の良い循環器薬　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I カテコラミン

P.10 掲載の参考文献
1) Jones AE, Shapiro NI, Trzeciak S et al : Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy : a randomized clinical trial. Jama 303 : 739-746, 2010
PubMed
2) Rivers E, Nguyen B, Havstad S et al : Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 : 1368-1377, 2001
PubMed
3) Hochman JS, Buller CE, Sleeper LA et al : Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome : a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol 36 : 1063-1070, 2000
PubMed
4) Menon V, White H, LeJemtel T et al : The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure : a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries in cardiogenic shock? J Am Coll Cardiol 36 : 1071-1076, 2000
PubMed
5) Antman EM, Anbe DT, Armstrong PW et al : ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 : e82-292, 2004
 
6) Sakr Y, Reinhart K, Vincent JL et al : Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely III Patients (SOAP) Study. Crit Care Med 34 : 589-597, 2006
 
7) De Backer D, Biston P, Devriendt J et al : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010
 
8) Bellomo R, Chapman M, Finfer S et al : Low-dose dopamine in patients with early renal dysfunction : a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356 : 2139-2143, 2000
 
9) Argalious M, Motta P, Khandwala F et al : "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 33 : 1327-1332, 2005
PubMed
P.16 掲載の参考文献
1) 日本循環器学会編 : 慢性心不全治療ガイドライン (2010年改訂版). 日本循環器学会, 2010
 
2) Kumar A, Choudhary G, Antonio C et al : Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 142 (3) : 512-515, 2001
PubMed
3) Cesario D, Clark J, Maisel A : Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure : a preliminary study. Am Heart J 135 (1) : 121-129, 1998
PubMed
4) Young JB, Moen EK : Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 19 (8 Suppl) : S49-57, 2000
 
5) Cuffe MS, Califf RM, Adams KF Jr et al : Short-term intravenous milrinone for acute exacerbation of chronic heart failure : a randomized controlled trial ; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. JAMA 287 (12) : 1541-1547, 2002
PubMed
6) Aranda JM Jr, Schofield RS, Pauly DF et al : Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation : a prospective, randomized trial. Am Heart J 145 (2) : 324-329, 2003
PubMed
7) Gorodeski EZ, Chu EC, Reese JR et al : Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail 2 (4) : 320-324, 2009
PubMed
8) Nieminen MS, Bohm M, Cowie MR et al : Executive summary of the guidelines on the diagnosis and treatment of acute heart failure : the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (4) : 384-416, 2005
 
P.22 掲載の参考文献
1) De Backer D, Biston P, Devriendt J et al : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010
 
2) Holmes CL et al : Bad medicine : low-dose dopamine in the ICU. Chest 123 : 1266-1275, 2003
PubMed
3) Goldberg LI, McDonald RH Jr, Zimmerman AM : Sodium diuresis produced by dopamine in patients with congestive heart failure. N Engl J Med 268 : 1060-1064, 1963
 
4) Szerlip HM : Renal-dose dopamine : fact and fiction. Ann Intern Med 115 : 153-154, 1991
PubMed
5) Thompson BT, Cockrill BA : Renal-dose dopamine : a siren song? Lancet 344 : 7-8, 1994
PubMed
6) Kellum JA : The use of diuretics and dopamine in acute renal failure : a systematic review of the evidence. Crit Care 1 : 53-59, 1997
PubMed
7) Belzberg H, Rivkind AL : Routine use of prophylactic renal-dose dopamine in surgical patients is not supported by the literature. Ann Surg 229 : 444-445, 1999
 
8) Bellomo R, Chapman M, Finfer S et al : Low-dose dopamine in patients with early renal dysfunction : a placebo-controlled randomized trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356 : 2139-2143, 2000
 
9) Kellum JA, Decker MJ : Use of dopamine in acute renal failure : a meta-analysis. Crit Care Med 29 : 1526-1531, 2001
 
10) Schunelle P, Gottmann U, Hoeger S et al : Effects of donor pretreatment with dopamine on graft function after kidney transplantation : a randomized controlled trial. JAMA 302 : 1067-1075, 2009
PubMed
11) Giamouzis G, Butler J, Starling RC et al : Impact of dopamine infusion on renal function in hospitalized heart failure patients ; results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 16 : 922-930, 2010
 
P.29 掲載の参考文献
1) Angus DC, Linde-Zwirble WT, Lidicker J et al : Epidemiology of severe sepsis in the United States : analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 : 1303-1310, 2001
PubMed
2) Annane D, Aegerter P, Jars-GuincestreMC, Guidet B : Current epidemiology of septic shock : the CUB-Rea Network. Crit Care Med 168 : 165-172, 2003
 
3) Friedman G, Silva E, Vincent JL : Has the mortality of septic shock changed with time. Crit CareMed 26 : 2078-2086, 1998
 
4) Dellinger RP, LevyMM, Rhodes A et al : Surviving Sepsis Campaign : International Guidelines of Severe Sepsis and Septic Shock, 2012. Intensive Care Med 39 (2) : 165-228, 2013
PubMed
5) Jones AE, Shapiro NI, Trzeciak S et al ; Emergency Medicine Shock Research Network (EMShockNet) Investigators : Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy : a randomized clinical trial. JAMA 303 (8) : 739-746, 2010
 
6) Havel C, Arrich J, Losert H et al : Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2011
 
7) De Backer D, Biston P, Devriendt J et al : SOAP II Investigators Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 (9) : 779, 2010
 
8) De Backer D, Aldecoa C, Njimi H, Vincent JL : Dopamine versus norepinephrine in the treatment of septic shock : a meta-analysis. Crit Care Med 40 (3) : 725-730, 2012
PubMed
9) Meier-Hellmann A, Reinhart K, Bredle DL et al : Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 25 (3) : 399, 1997
PubMed
10) Myburgh JA, Higgins A, Jovanovska A et al ; CAT Study investigators : A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34 (12) : 2226-2234, 2008 [Epub 2008 Jul 25]
 
11) Annane D, Vignon P, Renault A et al ; CATS Study Group : Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock : a randomised trial. Lancet 370 (9588) : 676, 2007
 
12) Mutlu GM, Factor P : Role of vasopressin in the management of septic shock. Intensive Care Med 30 : 1276-1291, 2004
PubMed
13) Sharshar T, Blanchard A, PaillardMet al : Circulating vasopressin levels in septic shock. Crit CareMed 31 (6) : 1752, 2003
 
14) Dunser MW, Mayr AJ, Ulmer H et al : Arginine vasopressin in advanced vasodilatory shock : a prospective, randomized, controlled study. Circulation 107 : 2313-2319, 2003
 
15) Kill C, Wranze E, Wulf H : Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol 134 (3) : 260, 2004
PubMed
16) Schummer C, Wirsing M, Schummer W : The pivotal role of vasopressin in refractory anaphylactic shock. Anesth Analg 107 (2) : 620, 2008
PubMed
17) James AR, Keith RW, Joel S et al ; for the VASST Investigators : Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. N Engl J Med 358 : 877-887, 2008
 
18) Russell JA, Walley KR, Gordon AC et al ; Dieter Ayers for the Vasopressin and Septic Shock Trial Investigators : Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37 (3) : 811-818, 2009
 
19) Polito A, Parisini E, Ricci A et al : Vasopressin for treatment of vasodilatory shock : an ESICMsystematic review and meta-analysis. Intensive Care Med 38 : 9-19, 2012
 
P.34 掲載の参考文献
1) Paradis NA, Martin GB, Goetting MG et al : Simultaneous aortic, jugular bulb, and right atrial pressures during cardiopulmonary resuscitation in humans. Insights into mechanisms. Circulation 80 : 361-368, 1989
PubMed
2) Sunde K, Steen PA : The Use of Vasopressor Agents During Cardiopulmonary Resuscitation. Crit Care Clin 28 : 189-198, 2012
PubMed
3) Olasveengen TM, Sunde K, Brunborg C et al : Intravenous drug administration during out-of-hospital cardiac arrest : a randomized trial. JAMA 302 : 2222-2229, 2009
PubMed
4) Holmberg M, Holmberg S, Herlitz J : Low chance of survival among patients requiring epinephrine or intubation after out-of-hospital cardiac arrest in Sweden. Resuscitation 54 : 37-45, 2002
PubMed
5) Cao L, Weil MH, Sun S et al : Vasopressor agents for cardiopulmonary resuscitation. J Cardiovasc Pharmacol Ther 8 : 115-121, 2003
PubMed
6) Lindberg L, Liao Q, Steen S : The effects of epinephrine/norepinephrine on end-tidal carbon dioxide concentration, coronary perfusion pressure and pulmonary arterial blood flow during cardiopulmonary resuscitation. Resuscitation 43 : 129-140, 2000
PubMed
7) Callaway CW : Epinephrine for cardiac arrest. Curr Opin Cardiol 28 : 36-42, 2013
PubMed
8) Ristagno G, Tang W, Huang L et al : Epinephrine reduces cerebral perfusion during cardiopulmonary resuscitation. Crit Care Med 37 : 1408-1415, 2009
PubMed
9) Hagihara A, Hasegawa M, Abe T et al : Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA 307 : 1161-1168, 2012
PubMed
10) Hayashi Y, Iwami T, Kitamura T et al : Impact of early intravenous epinephrine administration on outcomes following out-of-hospital cardiac arrest. Circ J 76 : 1639-1645, 2012
PubMed
11) 日本蘇生協議会 : ガイドライン 2010, 第2章 成人の二次救命処置 (ALS). http://jrc.umin.ac.jp/pdf/G2010_02_ALS_120208.pdf
 
12) Neumar RW, Otto CW, Link MS et al : Part 8 : adult advanced cardiovascular life support : 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122 : S729-767, 2010
PubMed
13) Deakin CD, Nolan JP, Soar J et al : European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support. Resuscitation 81 : 1305-1352, 2010
PubMed
14) Xanthos T, Bassiakou E,Koudouna E et al : Combination pharmacotherapy in the treatment of experimental cardiac arrest. Am J Emerg Med 27 : 651-659, 2009
PubMed
15) Deakin CD, Morrison LJ, Morley PT et al : Part 8 : Advanced life support : 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Resuscitation 81 : e93-e174, 2010
PubMed
16) Ditchey RV, Lindenfeld J : Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during closed-chest resuscitation in dogs. Circulation 78 : 382-389, 1988
PubMed
17) Mally S, Jelatancev A, Grmec S : Effects of epinephrine and vasopressin on end-tidal carbon dioxide tension and mean arterial blood pressure in out-of-hospital cardiopulmonary resuscitation : an observational study. Crit Care 11 : R39, 2007
PubMed
18) Fox AW, May RE, MitchWE : Comparison of peptide and nonpeptide receptor-mediated responses in rat tail artery. J Cardiovasc Pharmacol 20 : 282-289, 1992
PubMed
19) Wenzel V, Krismer AC, Arntz HR : A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 350 : 105-113, 2004
PubMed
20) Morris DC, Dereczyk BE, Grzybowski M : Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 4 : 878-883, 1997
PubMed
21) Ristagno G, Sun S, Tang W : Effects of epinephrine and vasopressin on cerebral microcirculatory flows during and after cardiopulmonary resuscitation. Crit Care Med 35 : 2145-2149, 2007
PubMed
22) Lindner KH, Prengel AW, Pfenninger EG et al : Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 91 : 215-221, 1995
PubMed
23) Wenzel V, Lindner KH, Krismer AC et al : Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 99 : 1379-1384, 1999
 
24) Mayr VD, Wenzel V, Voelckel WG et al : Developing a vasopressor combination in a pig model of adult asphyxial cardiac arrest. Circulation 104 : 1651-1656, 2001
 
25) Babar SI, Berg RA, Hilwig RW et al : Vasopressin versus epinephrine during cardiopulmonary resuscitation : a randomized swine outcome study. Resuscitation 41 : 185-192, 1999
PubMed
26) Guyette FX, Guimond GE, Hostler D et al : Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest. Resuscitation 63 : 277-282, 2004
PubMed
27) Gueugniaud PY, David JS, Chanzy E et al : Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. N Engl J Med 359 : 21-30, 2008
PubMed
28) Sillberg VA, Perry JJ, Stiell IG et al : Is the combination of vasopressin and epinephrine superior to repeated doses of epinephrine alone in the treatment of cardiac arrest-a systematic review. Resuscitation 79 : 380-386, 2008
PubMed
29) Popp E, Vogel P, Teschendorf P et al : Vasopressors are essential during cardiopulmonary resuscitation in rats : Is vasopressin superior to adrenaline? Resuscitation 72 : 137-144, 2007
PubMed
30) Gaieski DF, Band RA, Abella BS et al : Early goal-directed hemodynamic optimization combined with therapeutic hypothermia in comatose survivors of out-of-hospital cardiac arrest. Resuscitation 80 : 418-424, 2009
PubMed

II 降圧薬

P.43 掲載の参考文献
1) The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153 (2) : 154-183, 1993
PubMed
2) Wallach R, Karp RB, Reves JG et al : Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery : a study of hemodynamic and humoral factors. Am J Cardiol 46 (4) : 559-565, 1980
PubMed
3) Ault MJ, Ellrodt AG : Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med 3 (6 Suppl) : 10-15, 1985
 
4) Katz JN, Gore JM, Amin A et al : Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension : the Studying the Treatment of Acute hyperTension (STAT) registry. Am Heart J 158 (4) : 599-606, e1, 2009
 
5) Van den Born B-JH, Lowenberg EC, Van der Hoeven NV et al : Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 29 (5) : 922-927, 2011
 
6) Cohn JN, Franciosa JA, Francis GS et al : Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure : results of a Veterans Administration cooperative study. N Engl J Med 306 (19) : 1129-1135, 1982
 
7) Aronson S, Dyke CM, Stierer KA et al : The ECLIPSE trials : comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 107 (4) : 1110-1121, 2008
PubMed
8) Pollack CV, Varon J, Garrison NA et al : Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med 53 (3) : 329-338, 2009
PubMed
9) Narotam PK, Puri V, Roberts JMet al : Management of hypertensive emergencies in acute brain disease : evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. J Neurosurg 109 (6) : 1065-1074, 2008
 
10) Peacock WF, Varon J, Baumann BM et al : CLUE : a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care 15 (3) : R157, 2011
 
11) Grossman E, Messerli FH, Grodzicki T, Kowey P : Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 276 (16) : 1328-1331, 1996
PubMed
12) Vaughan CJ, Delanty N : Hypertensive emergencies. Lancet 356 (9227) : 411-417, 2000
PubMed
13) Marik PE, Varon J : Hypertensive crises : challenges and management. Chest 131 (6) : 1949-1962, 2007
PubMed
14) Khan IA, Nair CK : Clinical, diagnostic, and management perspectives of aortic dissection. Chest 122 (1) : 311-328, 2002
PubMed
P.50 掲載の参考文献
1) 日本脳卒中学会ガイドライン 2009. Available at : http://www.jsts.gr.jp/jss08.html.
 
2) Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 2001 : CD000039.
 
3) Adams HP Jr, del Zoppo G, Alberts MJ et al : Guidelines for the early management of adults with ischemic stroke : a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups : the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38 : 1655-1711, 2007
PubMed
4) Oliveira-Filho J, Silva SC, Trabuco CC et al : Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology 61 : 1047-1051, 2003
PubMed
5) Vlcek M, Schillinger M, Lang W et al : Association between course of blood pressure within the first 24 hours and functional recovery after acute ischemic stroke. Ann Emerg Med 42 : 619-626, 2003
PubMed
6) Castillo J, Leira R, Garcia MM et al : Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 35 : 520-526, 2004
PubMed
7) Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA : Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 33 : 1315-1320, 2002
PubMed
8) Ahmed N, Nasman P, Wahlgren NG : Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 31 : 1250-1255, 2000
PubMed
9) Potter JF, Robinson TG, Ford GA et al : Controlling hypertension and hypotension immediately post-stroke (CHHIPS) : a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 8 : 48-56, 2009
PubMed
10) Schrader J, Luders S, Kulschewski A et al : The ACCESS Study : evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 34 : 1699-1703, 2003
PubMed
11) Sandset EC, Bath PM, Boysen G et al : The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST) : a randomised, placebo-controlled, double-blind trial. Lancet 377 : 741-750, 2011
PubMed
12) Robinson TG, Potter JF, Ford GA et al : Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS) : a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 9 : 767-775, 2010
PubMed
13) Broderick J, Connolly S, Feldmann E et al : Guidelines for the management of spontaneous intracerebral hemorrhage in adults : 2007 update : a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38 : 2001-2023, 2007
 
14) Morgenstern LB, Hemphill JC, 3rd, Anderson C et al : Guidelines for the management of spontaneous intracerebral hemorrhage : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 41 : 2108-2129, 2010
PubMed
15) Dandapani BK, Suzuki S, Kelley RE et al : Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke 26 : 21-24, 1995
PubMed
16) Jauch EC, Lindsell CJ, Adeoye O et al : Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke 37 : 2061-2065, 2006
PubMed
P.59 掲載の参考文献
1) Beta Blocker Heart Attack Trial Research Group : A randomized trial of propranolol in patients with acute myocardial infarction : mortality results. JAMA 247 : 1707-1714, 1982
 
2) Guidelines for Diagnosis and Treatment of Patientswith Coronary Spastic Angina, Circulation Journal Vol. 72, Suppl. IV : 1199, 2008
 
3) Yasue H, Omote S, Takizawa A, Nagao M : Coronary arterial spasm in ischemic heart disease and its pathogenesis. A review. Circ Res 52 : 1147-1152, 1983
 
4) Kim JW, Suh SY, Choi CU et al : Six-Month Comparison of Coronary Endothelial Dysfunction Associated With Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent FREE. J Am Coll Cardiol Intv 1 (1) : 65-71, 2008
 
5) Pristipino C, Beltrame JF, Finocchiaro ML et al : Major racial differences in coronary constrictor response between Japanese and caucasians with recent myocardial infarction. Circulation 101 (10) : 1102-1108, 2000
PubMed
6) The Japanese b-blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93 (8) : 969-973, 2004
 
7) Bangalore S, Steg G, Deedwania P et al : REACH Registry Investigators. b-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308 (13) : 1340-1349, 2012
 
P.66 掲載の参考文献
1) Auerbach AD, Goldman L : Beta-blockers and reduction of cardiac events in noncardiac surgery. JAMA 287 : 1435-1444, 2002
PubMed
2) London MJ, Zaugg M, Schaub MC, Spahn DR : Perioperative beta-adrenergic receptor blockade. Anesthesiology 100 : 170, 2004
PubMed
3) Stevens RD, Burri H, Tramer MR : Pharmacologic myocardial protection in patients undergoing noncardiac surgery : A quantitative systematic review. Anesth Analg 97 : 623, 2003
PubMed
4) POISE Study Group : Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial) : A randomised controlled trial. Lancet 371 : 1838, 2008
 
5) Fleisher LA, Beckman JA, Brown KA et al : 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery : A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120 : e169, 2009
 
6) Bangalore S, Wetterslev J, Pranesh S et al : Perioperative beta blockers in patients having non-cardiac surgery : a meta-analysis. Lancet 372 : 1962-1976, 2008 Epub 2008. Nov 13.
 

III 抗血小板薬・抗凝固薬

P.74 掲載の参考文献
1) 日本循環器学会ガイドライン 2009年改訂版. 循環器疾患における抗凝固・抗血小板療法に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf
 
2) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group : Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction : ISIS-2. Lancet 2 (8607) : 349-360, 1988
PubMed
3) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 : 71-86, 2002
PubMed
4) 脳卒中治療ガイドライン委員会 : 脳卒中治療ガイドライン 2009. http://www.jsts.gr.jp/jss08.html
 
5) HIT情報センター : ヘパリン起因性血小板減少症. www.hit-center.jp
 
P.83 掲載の参考文献
1) Ogawa S, Koretsune S, Yasaka M et al : Antithrombotic Therapy in Atrial Fibrillation-Evaluation and Positioning of New Oral Anticoagulant Agents-. Circ J 75 : 1539-1547, 2011
 
2) Olesen JB, Torp-Pedersen C, Hansen ML et al : The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1 : A nationwide cohort study. Thromb Haemost 107 : 1172-1179, 2012
PubMed
3) Camm AJ, Lip GYH, Caterina RD et al : 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : An update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart 14 : 1385-1413, 2012
 
4) Gage BF, Waterman AM, Shannon W et al : Validation of Clinical Classification Schemes for Predicting Stroke : Results From the National Registry of Atrial Fibrillation. JAMA 285 (22) : 2864-2870, 2001
 
5) Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation : Analysis of Pooled Data From Five Randomized Controlled Trial. Arch Intern Med 154 : 1449-1457, 1994
PubMed
6) Toyoda K, Yasaka M, Iwade K et al : Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 39 : 1740-1745, 2010
 
7) Connolly SJ, Ezekowitz MD, Yusuf S et al : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 : 1139-1151, 2009
PubMed
8) Eikelboom JW et al : Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger PatientsWith Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation 123 : 2363-2372, 2011
 
9) Patel MR, Mahaffey KW, Garg J et al : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 : 883-891, 2011
PubMed
10) Hori M,Matsumoto M, Tanahashi N et al : Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study-. Circ J 76 : 2104-2111, 2012
 
11) Granger CB, Alexander JH, McMurray JJ et al : Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 365 : 981-992, 2011
PubMed
12) Poli D, Antonucci E, Testa S et al : Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment : Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation. Circulation 124 : 824-829, 2011
 
P.90 掲載の参考文献
1) Samuel ZG : Chapter 77 Pulmonary Embolism. In "Braunwald's Heart Disease, 9th ed." Elsevire Saunders, Philadelphia, p1679, 2012
 
2) British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group : British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58 (6) : 470-483, 2003 doi : 10.1136/thorax.58.6.470
 
3) Kearon C, Kahn SR, Agnelli G et al : Antithrombotic therapy for venous thromboembolic disease : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 (6 Suppl) : 454S-545S, 2008 doi : 10.1378/chest.08-0658.
 
4) Quinlan DJ, McQuillan A, Eikelboom JW : Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism : a meta-analysis of randomized, controlled trials. Ann Intern Med 140 (3) : 175-183, 2004 PubMed PMID : 14757615
 
5) Oliveira GB, Crespo EM, Becker RC et al : Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 168 : 94, 2008
PubMed
6) Baroletti S, Piovella C, Fanikos J et al : Heparin-induced thrombocytopenia (HIT) : Clinical and economic outcomes. Thromb Haemost 100 : 1130, 2008
PubMed
7) Arepally GM, Ortel TL : Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355 : 809, 2006
PubMed
8) Hull RD : Treatment of pulmonary embolism : The use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost 99 : 502, 2008
PubMed
9) Antman EM, Hand M, Armstrong PW et al : 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 117 (2) : 296-329, 2008 doi : 10.1161/CIRCULATIONAHA.107.188209
 
10) Antman EM, Morrow DA, McCabe CH et al : Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 : 1477, 2006
PubMed
11) Murphy SA, Gibson CM, Morrow DA et al : Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum : a meta-analysis. Eur Heart J 28 (17) : 2077-2086, 2007 doi : 10.1093/eurheartj/ehm224
 
12) Yusuf S, Mehta SR, Chrolavicius S et al : Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : The OASIS-6 randomized trial. JAMA 295 : 1519, 2009
 
13) Stone GW, Witzenbichler B, Guagliumi G et al : Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 : 2218, 2008
PubMed
14) Oldgren J, Wallentin L, Afzal R et al : Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 29 : 315, 2008
 
15) Buller HR, Davidson BL, Decousus H et al : Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis : a randomized trial. Ann Intern Med 140 (11) : 867-873, 2004 PMID : 15172900
 
16) Buller HR, Davidson BL, Decousus H et al : Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (18) : 1695-1702, 2003 doi : 10.1056/NEJMoa035451
 
17) Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators : Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (14) : 1464-1476, 2006 doi : 10.1056/NEJMoa055443
 
18) Baroletti S, Labreche M, Niles M et al : Prescription of fondaparinux in hospitalised patients. Thromb Haemost 101 : 1091, 2009
PubMed
P.97 掲載の参考文献
1) Yusuf S, Zhao F, Mahta SR et al : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 345 (7) : 494-502, 2001
 
2) Steinhubl SR, Berger PB, Mann JT III et al : Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention : a randomized controlled trial. JAMA 288 : 2411-2420, 2002
 
3) 2011 ACCF/AHA/SCAI Guideline for Percutasous Coronary Intervention.
 
4) 安定冠動脈疾患における待機的PCIのガイドライン (JCS 2011)
 
5) Pfisterer M, Brunner-La Rocca HP, Buser PT et al : BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug- eluting stents : an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 : 2584-2591, 2006
PubMed
6) Park SJ, Park DW, Kim YH et al : Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Eng J Med 362 : 1374-1382, 2010
 
7) Valgimigli M, Campo G, Monti M et al : Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting : a randomized multicenter trial. Circulation 125 (16) : 2015-2026, 2012
PubMed
8) Tada T, Natuaki M, Morimoto T et al : Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation. Circ Cardiovasc INterv 5 : 381-391, 2012
 
9) Wiviott SD, Braunwald E, McCabe CH et al : Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 : 2001-2015, 2007
PubMed
10) Wallentin L, Becker RC, Budai A et al : Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 361 : 1045-1057, 2009
 
11) Mehta SR, Rassand JP, Chrolavicius S et al : Dose comparison of clopidogrel and aspirin in acute coronary syndromes. N Eng J Med 363 (10) : 930-942, 2010
 
12) Price MJ, Berger PB, Teirstein PS et al : Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention : the GRAVITAS randomized tiral. JAMA 305 (11) : 1097-1105, 2011
 
P.106 掲載の参考文献
1) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group : Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 : 1581-1587, 1995
 
2) National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group : Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 340 : 1781-1787, 1999
 
3) Yamaguchi T, Mori E, Minematsu K et al : Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset : Japan Alteplase Clinical Trial (J-ACT). Stroke 37 : 1810-1815, 2006
PubMed
4) Hacke W, Kaste M, Bluhmki E et al : Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 : 1317-1329, 2008
PubMed
5) The IST-3 collaborative group : The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international stroke trial [IST-3]) : a randomised controlled trial. Lancet 379 : 2352-2363, 2012
 
6) Wardlaw JM, Murray V, Berge E et al : Recombinant tissue plasminogen activator for acute ischaemic stroke : an updated systematic review and meta-analysis. Lancet 379 : 2364-2372, 2012
PubMed
7) ParsonsM, Spratt N, Bivard A et al : A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366 : 1099-1107, 2012
 
8) Broderick JP, Palesch YY, Demchuk AM et al : Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368 : 893-903, 2013
PubMed
9) Ciccone A, Valvassori L, Nichelatti M et al : Endovascular treatment for acute ischemic stroke. N Engl J Med 368 : 904-913, 2013
PubMed
10) Wan S, Quinlan DJ, Agnelli G, Eikelboom JW : Thrombolysis compared with heparin for the initial treatment of pulmonary embolism : a meta-analysis of the randomized controlled trials. Circulation 110 (6) : 744-749, 2004 Epub 2004 Jul 19
 
11) Konstantinides S, Geibel A, Heusel G et al : Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators : Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347 : 1143-1150, 2002
 
12) The Pulmonary Embolism Thrombolysis (PEITHO) Trial Steering Committee : Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury : rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 163 (1) : 33-38.e1, 2012 Clinical Trials. gov Identifier : NCT00639743
 
13) Clot Dissolving Treatment for Blood Clots in the Lungs. Tenecteplase Or Placebo : Cardiopulmonary Outcomes At Three Months [TOPCOAT] ; Clinical Trials. gov Identifier : NCT00680628
 
脳卒中合同ガイドライン委員会 : 脳卒中治療ガイドライン 2009 http://www.jsnt.gr.jp/guideline/img/nou2009_02.pdf
 
Executive summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2 Suppl) : 7S-47S, 2012 doi : 10.1378/chest.1412S3.
 
Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke 44 : 870-947, 2013 http://stroke.ahajournals.org/content/44/3/870
 
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008 Guidelines Update 2009 (Should the time window for intravenous thrombolysis be extended?) http://www.eso-stroke.org/recommendations.php?cid=9&sid=1
 
日本循環器学会肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf
 
Executive summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2 Suppl) : 7S-47S, 2012 doi : 10.1378/chest.1412S3.
 
AHA Scientific Statement : Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. Circulation 123 : 1788-1830, 2011 http://circ.ahajournals.org/content/123/16/1788
 
Guidelines on the diagnosis and management of acute pulmonary embolism : The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29 (18) : 2276-2315, 2008 http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/acute-pulmonary-embolism.aspx
 
P.119 掲載の参考文献
1) Fleisher LA, Beckman JA, Brown KA et al : ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery : Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 116 : 1971-1996, 2007
 
2) Brilakis ES, Banerjee S, Berger PB : Perioperative management of patients with coronary stents. J Am Coll Cardiol 49 : 2145-2150, 2007
PubMed
3) Riddell JW, Chiche L, Plaud B, HamonM : Coronary stents and noncardiac surgery. Circulation 116 : e378-382, 2007
PubMed
4) Broad L, Lee T, Conroy M et al : Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth 98 : 19-22, 2007
 
5) Harder S, Klinkhardt U, Alvarez JM : Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy : pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 43 : 963-981, 2004
PubMed
6) Pisters R, Lane DA, Nieuwlaat R et al : A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey. Chest 138 : 1093-1100, 2010
PubMed
7) Kleinow ME, Garwood CL, Clemente JL, Whittaker P : Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 17 : 523-530, 2011
 
8) Holbrook AM, Pereira JA, Labiris R et al : Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165 : 1095-1106, 2005
PubMed
9) Jaffer AK, Brotman DJ, Bash LD et al : Variations in perioperative warfarin management : outcomes and practice patterns at nine hospitals. Am J Med 123 : 141-150, 2010
PubMed
10) Garcia DA, Regan S, Henault LE et al : Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 168 : 63-69, 2008
PubMed
11) White RH,McKittrick T, Hutchinson R, Twitchell J : Temporary discontinuation of warfarin therapy : changes in the international normalized ratio. Ann Intern Med 122 : 40-42, 1995
PubMed
12) Garcia DA, Granger CB : Anticoagulation, novel agents, and procedures : can we pardon the interruption? Circulation 126 : 255-257, 2012
PubMed
13) Siegal D, Yudin J, Kaatz S et al : Periprocedural heparin bridging in patients receiving vitamin K antagonists : systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126 : 1630-1639, 2012
PubMed
14) Healey JS, Eikelboom J, Douketis J et al : Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin : results from the Randomized Evaluation of Long-TermAnticoagulation Therapy (RE-LY) randomized trial. Circulation 126 : 343-348, 2012
PubMed
15) van Ryn J, Stangier J, Haertter S et al : Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103 : 1116-1127, 2010
PubMed
16) Yasaka M, Sakata T, Minematsu K, Naritomi H : Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 108 : 25-30, 2002
PubMed
17) Eerenberg ES, Kamphuisen PW, Sijpkens MK et al : Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate : a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124 : 1573-1579, 2011
PubMed
18) Kaatz S, Kouides PA, Garcia DA et al : Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87 (Suppl 1) : S141-145, 2012
 
19) Warkentin TE, Margetts P, Connolly SJ et al : Recombinant factor VIIa (rF VIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119 : 2172-2174, 2012
 

IV 急性心不全で選択する薬剤

P.128 掲載の参考文献
1) Mebazaa A, Pitsis AA, Rudiger A et al : Clinical review : practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical care 14 : 201, 2010
 
2) Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K : Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circulation journal : official journal of the Japanese Circulation Society 69 : 283-290, 2005
PubMed
3) Kasama S, Toyama T, Kumakura H et al : Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 45 : 1108-1113, 2004
PubMed
4) Hayashi M, Tsutamoto T, Wada A et al : Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. Journal of the American College of Cardiology 37 : 1820-1826, 2001
PubMed
5) McMurray JJ, Adamopoulos S, Anker SD et al : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 33 : 1787-1847, 2012
 
6) Heart Failure Society of A, Lindenfeld J, Albert NM et al : HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of cardiac failure 16 : e1-194, 2010
PubMed
7) Kajimoto K, Sashida Y, Minami Y et al : Systolic blood pressure at admission as a predictor of the response to initial carperitide therapy in patients hospitalized for acute decompensated heart failure with left ventricular systolic dysfunction. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy 23 : 481-488, 2009
 
8) Kosuge M, Miyajima E, Kimura K et al : Comparison of atrial natriuretic peptide versus nitroglycerin for reducing blood pressure in acute myocardial infarction. The American journal of cardiology 81 : 781-784, 1998
PubMed
9) Wakui S, Sezai A, Tenderich G et al : Experimental investigation of direct myocardial protective effect of atrial natriuretic peptide in cardiac surgery. The Journal of thoracic and cardiovascular surgery 139 : 918-925, 2010
PubMed
10) Ishikawa C, Tsutamoto T, Wada A et al : Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure. Journal of cardiovascular pharmacology 46 : 513-518, 2005
PubMed
11) Schwartzenberg S, Redfield MM, From AM et al : Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. Journal of the American College of Cardiology 59 : 442-451, 2012
PubMed
12) Cotter G, Moshkovitz Y, Kaluski E et al : The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. European journal of heart failure 5 : 443-451, 2003
PubMed
13) Ross J Jr : Afterload mismatch and preload reserve : a conceptual framework for the analysis of ventricular function. Progress in cardiovascular diseases 18 : 255-264, 1976
PubMed
P.136 掲載の参考文献
1) Stevenson LW, Tillisch JH, Hamilton M et al : Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. AJC 66 (19) : 1348-1354, 1990
 
2) Wilson JR, Reichek N, Dunkman WB, Goldberg S : Effect of diuresis on the performance of the failing left ventricle in man. The American Journal of Medicine 70 (2) : 234-239, 1981
PubMed
3) Felker G, Lee K, Bull D et al : Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine 364 (9) : 797-805, 2011
PubMed
4) Salvador DRK, Punzalan FE, Romous GC : Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Datebase of Systematic Reviews 2005, Issue 3, pp1-28, 2013
 
5) Eshaghian S, Horwich TB, Fonarow GC : Relation of Loop Diuretic Dose toMortality in Advanced Heart Failure. The American journal of cardiology 97 (12) : 1759-1764, 2006
 
6) Bouchard JEE, Soroko SB, Chertow GM et al : Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney International 76 (4) : 422-427, 2009
 
7) Neuberg GW, Miller AB, O'Connor CM et al : Diuretic resistance predicts mortality in patients with advanced heart failure. American Heart Journal 144 (1) : 31-38, 2002
PubMed
8) Nohria A, Hasselblad V, Stebbins A et al : Cardiorenal interactions : insights from the ESCAPE trial. Journal of the American College of Cardiology 51 (13) : 1268-1274, 2008
PubMed
9) Mullens W, Abrahams Z, Francis GS et al : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. Journal of the American College of Cardiology 53 (7) : 589-596, 2009
PubMed
10) Klein L : Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure : Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study. Circulation 111 (19) : 2454-2460, 2005
 
11) Gheorghiade M, Rossi JS, Cotts W et al : Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 167 (18) : 1998-2005, 2007
PubMed
12) Paterna S, Di Pasquale P, Parrinello G et al : Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure : a double-blind study. JAC 45 (12) : 1997-2003, 2005
 
13) KonstamMA, Gheorghiade M, Burnett JC et al : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA 297 (12) : 1319-1331, 2007
PubMed
P.143 掲載の参考文献
1) Willenheimer R, van Veldhuisen DJ, Silke B et al : Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart FailureWith Bisoprolol Followed by Enalapril, as ComparedWith the Opposite Sequence : Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112 : 2426-2435, 2005
 
2) Clinical outcome with enalapril in symptomatic chronic heart failure ; a dose comparison. European Heart Journal 19 : 481-489, 1998
 
3) Bristow MR, Gilbert EM, Abraham WT et al : Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure. Circulation 94 : 2807-2816, 1996
PubMed
4) Hori M, Sasayama S, Kitabatake A et al : Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure : the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. American Heart Journal 147 : 324-330, 2004
PubMed
5) Konstam MA, Poole-Wilson PA, Dickstein K et al : Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. European Journal of Heart Failure 10 : 899-906, 2008
PubMed
6) Packer M, Poole-Wilson PA, Armstrong PW et al : Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. Circulation 100 : 2312-2318, 1999
PubMed
7) Gattis WA, O'Connor CM, Gallup DS et al : Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure : Results of the initiation management predischarge : process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial. Journal of the American College of Cardiology 43 : 1534-1541, 2004
PubMed
8) Swedberg K, Komajda M, Bohm M et al : Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure : Is There an Influence of Beta-Blocker Dose? : Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study. Journal of the American College of Cardiology 59 : 1938-1945, 2012
PubMed
9) Swedberg K, Komajda M, Bohm M et al : Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo-controlled study. The Lancet 376 : 875-885, 2010
 
10) Dzau VJ : Tissue Angiotensin and Pathobiology of Vascular Disease : A Unifying Hypothesis. Hypertension 37 : 1047-1052, 2001
PubMed
11) Tsikouris JP, Suarez JA, Meyerrose GE et al : Questioning a Class Effect : Does ACE Inhibitor Tissue Penetration Influence the Degree of Fibrinolytic Balance Alteration following an Acute Myocardial Infarction? The Journal of Clinical Pharmacology 44 : 150-157, 2004
 
12) Collaboration BPLTT. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. Journal of Hypertension 25 : 951-958, 2007 doi : 10.1097/HJH.0b013e3280bad9b4.
 
13) Poole-Wilson PA, Swedberg K, Cleland JGF et al : Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) : randomised controlled trial. The Lancet 362 : 7-13, 2003
 
14) Mu S, Shimosawa T, Ogura S et al : Epigenetic modulation of the renal [beta] -adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med 17 : 573-580, 2011
PubMed
15) Dutta P, Courties G, Wei Y et al : Myocardial infarction accelerates atherosclerosis. Nature 487 : 325-329, 2012
PubMed
16) Zannad F, McMurray JJV, Krum H et al : Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine 364 : 11-21, 2011
PubMed
17) The ESG. Effects of Pimobendan on Adverse Cardiac Events and Physical Activities in Patients With Mild to Moderate Chronic Heart Failure The Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Circulation Journal 66 : 149-157, 2002
 
18) The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine 336 : 525-533, 1997
PubMed

V 抗不整脈薬

P.153 掲載の参考文献
1) Van Gelder IC, Groenveld HF, Crijns HJ et al : Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362 : 1363-1373, 2010
PubMed
2) Lundstrom T : Ventricular rate control and exercise performance in chronic atrial flbrillation : effects of diltiazem and verapamil. J Am Coll Cardiol 16 : 86-90, 1990
PubMed
3) Olshansky B, Rosenfeld LE, Warner AL et al : The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study : approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43 : 1201-1208, 2004
PubMed
4) 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 57 : e101-198, 2011
PubMed
P.160 掲載の参考文献
1) 日本循環器学会編 : 心房細動治療 (薬物) ガイドライン (2008年改訂版). Circ J 72 (Suppl IV) : 1581-1638, 2008
 
2) Wyse DG et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 : 1825-1833, 2002
PubMed
3) Hohnloser SH et al : Rhythm or rate control in atrial fibrillation-Pharmacological interention in Atrial Fibrillation (PIAF) : a randomized trial. Lancet 356 : 1789-1794, 2000
 
4) Hagens VE et al : Quality of Life in persistent atrial fibrillation in the RACE study. Circulation 106 : II 634, 2002
 
5) Carlsson J et al : Randomized trial of rate-control in persistent atrial fibrillation : the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 : 1690-1696, 2003
PubMed
6) Ogawa S et al : Optimal treatment strategy for patients with paroxysmal atrial fibrillation (J-RHYTHMstudy). Circ J 73 (2) : 242-248, 2009
PubMed
7) Atarashi H et al : Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Supression Trial on Atrial Fibrillation). Am J Cardiol 78 : 694-697, 1996
 
8) Atarashi H et al : Doseresponse effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephhonic electrocardiography-A multicenter, placebo-controlled, double-blind trial-. Circ J 71 : 294-300, 2007
 
9) Nakazato Y et al : Conversion and Maintenance of Sinus Rhythm by Bepridil in Patients With Persistent Atrial Fibrillation. Circ J 60 : 44-48, 2005
 
10) Yamashita T et al : Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrograms : a multicenter randomized, placebo-controlled, double-blind study (J-BAF study). Circ J 73 : 1020-1027, 2009
 
11) Denis R et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 : 2667-2677, 2008
 
12) Prakash CD et al : Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation : Observations from the veterans affairs congestibe heart failure survibal trial of antiarrhythmic therapy (CHF-STAT). Circ 98 : 2574-2579, 1998
 
13) Hohnloser SH et al : Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrythmias. Am J Cardiol 70 : A3-A10, 1992
 
14) Morita N et al : Effect of nifecalant for acute conversion of atrial flutter. The possible terminstion mechanism of typical atrial flutter. PACE 30 : 1242-1253, 2007
PubMed
15) 日本循環器学会編 : 不整脈の非薬物治療ガイドライン (2011年改訂版). Circ J 17, 2012 http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf
 
16) Lutomsky BA et al : Catheter ablation of paroxysmal atrial fibrillation improves cardiac function : a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging. Europace 10 : 593-599, 2008
PubMed
17) Khan MN et al : Pulmonary vein isolation for atrial fibrillation in patients with symptomatic sinus bradycardia or pauses. J Cardiovasc Electorophysiol 15 : 784-789, 2004
PubMed
P.169 掲載の参考文献
1) 日本心電学会抗不整脈薬ガイドライン委員会報告 : Sicilian Gambitに基づく抗不整脈薬選択のガイドライン作成に向けて. 心電図 17 : 191-197, 1997
 
2) サンリズム(R) カプセル 25 mg, カプセル 50 mg医薬品インタビューフォーム, 第一三共, 2011
 
3) Atarashi H, Inoue H, Hiejima K et al : Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation) : the PSTAF Investigators. Am J Cardiol 78 : 694-697, 1996
PubMed
4) 加藤和三, 佐久間昭, 新博次他 : 塩酸ピルジカイニド注射剤〔SUN1165 (注) 〕の発作性心房細動・粗動停止効果-プラセボを対照薬とした多施設二重盲検群間比較試験-. 臨床医薬 14 : 769-790, 1998
 
5) Kumagai K, Abe H, Hiraki T et al : Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation : a multicenter trial. Pacing Clin Electrophysiol 23 (11 Pt 2) : 1880-1882, 2000
 
6) Okishige K, Fukunami M, Kumagai K et al : Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide : pilsicainide suppression trial for persistent atrial fibrillation II. Circ J 70 : 657-661, 2006
PubMed
7) Komatsu T, Sato Y, Tachibana H et al : Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation : influence of the duration of arrhythmia before therapy. Circ J 70 : 667-672, 2006
 
8) Ogawa S, Yamashita T, Yamazaki T et al : Optimal treatment strategy for patients with paroxysmal atrial fibrillation. -J-RHYTHM Study-. Circ J 73 : 242-248, 2009
PubMed
9) 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告) 心房細動治療 (薬物) ガイドライン (2008年改訂版). Circ J 72 (suppl. IV) : 1581-1638, 2008
 
10) 新谷博一, 加藤和三, 杉本恒明他 : SUN 1165の心室性期外収縮に対する臨床評価-用量検討のための多施設二重盲検比較試験-. 臨床薬理 20 : 719-733, 1989
 
11) Sakanashi M, Noguchi K, Matsuzaki T et al : Effects of pilsicainide on systemic hemodynamics and cardiac function of anesthetized dogs. Cardioscience 4 : 241-250, 1993
PubMed
12) 井野威, 新博次, 斎藤寛和他 : SUN 1165単回経口投与の電気生理学的効果ならびに心血行動態に及ぼす影響-発作性上室性頻拍例における検討-. 臨床薬理 20 : 677-685, 1989
 
13) Kajimoto K, Imai T, Minami Y et al : Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol 106 : 1307-1312, 2010
PubMed
14) 戸叶隆司, 中田八洲郎, 住吉正孝他 : Pilsicainide単回投与により著明な洞徐脈, 心室内伝導障害およびQT延長をきたした1例. 心電図 16 : 289-296, 1996
 
15) Horita Y, Kanaya H, Uno Y et al : A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings. Jpn Heart J 45 : 1049-1056, 2004
PubMed
16) Chinushi M, Komura S, Izumi D et al : Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome. Pacing Clin Electrophysiol 30 : 662-671, 2007
PubMed
17) Sadanaga T, Araki S, Tanaka Y et al : Spontaneous polymorphic ventricular tachycardia after administration of pilsicainide in a patient resuscitated from ventricular fibrillation. Pacing Clin Electrophysiol 29 : 1016-1018, 2006
 
18) Kaneko Y, Nakajima T, Kato T et al : Pilsicainide-induced polymorphic ventricular tachycardia. InternMed 51 : 443-444, 2012
PubMed
P.176 掲載の参考文献
1) Kudenchuk PJ, Cobb LA, Copass MK et al : Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Eng J Med 341 (12) : 871-878, 1998
 
2) Dorian P, Cass D, Schwartz B et al : Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Eng J Med 346 (12) : 884-890, 2002
 
3) Somberg JC, Bailin SJ, Haffajee CI et al : Intravenous Lidocaine Versus Intravenous Amiodarone (in a New Aqueous Formulation) for Incessant Ventricular Tachycardia. Am J Cardiol 90 (8) : 853-859, 2002
 
4) Sadowski ZP, Alexander JH, Skrabucha B et al : Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 137 (5) : 792-798, 1999
 
5) Desai AD, Chun S, Sung RJ : The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Int Med 127 (4) : 294-303, 1997
PubMed
6) Kowey PR, Marinchak RA, Rials SJ et al : Intravenous Amiodarone. J Am Col Cardiol 29 (6) : 1190-1198, 1997
 
7) Hazinski MF, Nolan JP, Billi JE et al : 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 122 : S250-275, 2010
PubMed
8) Gorgels APM, van den Dool A, Hofs A et al : Comparison of Procainamide and Lidocaine in Terminating Sustained Monomorphic Ventricular Tachycardia. Am J Cardiol 78 (1) : 43-46, 1996
 
P.182 掲載の参考文献
1) Tahara Y, Kimura K, Kosuge M et al : Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circulation journal 70 : 442-446, 2006
PubMed
2) Kudenchuk PJ, Cobb LA, Copass MK et al : Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. The New England journal of medicine 341 : 871-878, 1999
PubMed
3) Dorian P, Cass D, Schwartz B et al : Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. The New England journal of medicine 346 : 884-890, 2002
PubMed
4) Neumar RW, Otto CW, Link MS et al : Part 8 : Adult advanced cardiovascular life support : 2010 american heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 122 : S729-767, 2010
PubMed
5) Amino M, Yoshioka K, Opthof T et al : Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. Journal of cardiovascular pharmacology 55 : 391-398, 2010
PubMed

VI その他の身近な疑問

P.194 掲載の参考文献
1) Jessup M, Abraham WT, Casey DE et al : 2009 focused update : ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 : 1977-2016, 2009
 
2) Harshaw CW, Grossman W, Munro AB et al : Reduced systemic vascular resistance as therapy for severe mitral regurgitation of valvular origin. Ann Intern Med 83 : 312-316, 1975
PubMed
3) Hachenberg T, Mollhoff T, Holst D et al : Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension. J Cardiothorac Vasc Anesth 11 : 453-457, 1997
PubMed
P.207 掲載の参考文献
1) Li JS, Sexton DJ, Mick N et al : Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30 (4) : 633-638, 2000
 
2) Fowler VG Jr, Li J, Corey GR et al : Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia : experience in 103 patients. J Am Coll Cardiol 30 : 1072-1078, 1997
PubMed
3) Bayer AS, Bolger AF, Taubert KA et al : Diagnosis and management of infective endocarditis and its complications. Circulation 98 : 2936-2948, 1998
PubMed
4) Baddour LM, Wilson WR, Bayer AS et al : Infective endocarditis : diagnosis, antimicrobial therapy, and management of complications : a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association : endorsed by the Infectious Diseases Society of America. Circulation 111 (23) : e394-434, 2005
 
5) Gould FK, Denning DW, Elliott TSJ et al : Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults : a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 67 (2) : 269-289, 2012
PubMed
6) Habib G, Hoen B, Tornos P et al : Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009) : the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 30 (19) : 2369-2413, 2009
 
7) Ramsdale DR, Turner-Stokes L : Prophylaxis and treatment of infective endocarditis in adults : a concise guide. Clin Med 4 : 545-550, 2004
PubMed
8) Murdoch DR, Corey GR, Hoen B et al : Clinical presentation, etiology, and outcome of infective endocarditis in the 21 st century : the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169 (5) : 463-473, 2009
 
9) Ruoff K : Nutritionally variant streptococci. Clin Microbiol Rev 4 (2) : 184-190. 1991
PubMed
10) Kang DH, Kim YJ, Kim SH et al : Early Surgery versus Conventional Treatment for Infective Endocarditis. N Engl J Med 366 : 2466-2473, 2012
PubMed
11) RoeMT, AbramsonMA, Li J et al : Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the Duke criteria. Am Heart J 139 : 945-951, 2000
PubMed
12) Daniel WG, Mugge A, Grote J et al : Comparison of transthoracic and transesophageal echocardiography for detection of abnormalities of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol 71 : 210-215, 1993
PubMed
13) Blumberg EA, Karalis DA, Chandrasekaran K et al : Endocarditis-associated paravalvular abscesses. Do clinical parameters predict the presence of abscess? Chest 107 : 898-903, 1995
PubMed
14) Fowler VG Jr, Boucher HW, Corey GR et al : Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 : 653-665, 2006
PubMed
15) Liu C, Bayer A, Cosgrove SE et al : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52 (3) : e18-55, 2011
 
16) Leclercq R, Bingen E, Su QH et al : Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 35 : 92-98, 1991
PubMed
17) Caron F, Kitzis MD, Gutmann L et al : Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 36 : 2611-2616, 1992
PubMed
18) Credito, K., Lin G, Appelbaum PC : Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology, Antimicrob Agents Chemother 51 : 1504-1507, 2007
PubMed
P.220 掲載の参考文献
1) Shakespeare W. Hamlet. http://shakespeare.mit.edu/hamlet/full.html. Accessed March 17, 2013
 
2) Massie BM : Heart Failure : Pathophysiology and Diagnosis. In "Cecil RL, Goldman L, Schafer AI. Goldman's Cecil medicine. 24th ed." Chapter 58, Elsevier Saunders, Philadelphia, 2012
 
3) Nohria A, Lewis E, Stevenson LW : Medical management of advanced heart failure. JAMA 287 (5) : 628-640, 2002
PubMed
4) Grady KL, Dracup K, Kennedy G et al : Team management of patients with heart failure : A statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association. Circulation 102 (19) : 2443-2456, 2000
 
5) Marik PE, Cavallazzi R, Vasu T, Hirani A : Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients : a systematic review of the literature. Crit Care Med 37 (9) : 2642-2647, 2009
PubMed
6) Fuhlbrigge AL, Choi AMK : Diagnostic Procedures in Respiratory Disease. In "Longo DL. Harrison's principles of internal medicine. 18th ed." Chapter 253, McGraw-Hill, New York, 2012
 
7) Feissel M, Michard F, Faller JP, Teboul JL : The respiratory variation in inferior vena cava diameter as a guide to fluid therapy. Intensive Care Med 30 (9) : 1834-1837, 2004
PubMed
8) Nohria A, Tsang SW, Fang JC et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 (10) : 1797-1804, 2003
PubMed
9) Drazner MH, Hellkamp AS, Leier CV et al : Value of clinician assessment of hemodynamics in advanced heart failure : the ESCAPE trial. Circ Heart Fail 1 (3) : 170-177, 2008
PubMed
10) McGee SR : Evidence-based physical diagnosis. PA : Saunders, Philadelphia, 2001
 
11) Marik PE, Baram M, Vahid B : Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 134 (1) : 172-178, 2008
PubMed
12) Otto CM : Textbook of clinical echocardiography. 4th ed. PA : Elsevier/Saunders, Philadelphia, 2009
 
13) Lichtenstein DA, Meziere GA, Lagoueyte JF et al : A-lines and B-lines : lung ultrasound as a bedside tool for predicting pulmonary artery occlusion pressure in the critically ill. Chest 136 (4) : 1014-1020, 2009
 
14) Lichtenstein DA, Menu Y : A bedside ultrasound sign ruling out pneumothorax in the critically ill. Lung sliding. Chest 108 (5) : 1345-1348, 1995
PubMed
P.232 掲載の参考文献
1) Metra M, Cotter G, Gheorghiade M et al : The role of kidney in heart failure. Eur Heart J 33 : 2135-2143, 2012
PubMed
2) Ronco C, Happio M, House AA et al : Cardiorenal syndrome. J Am Coll Cardiol 52 : 1527-1539, 2008
 
3) Ismail Y, Kasmikha Z, Green HL et al : Cardio-renal syndrome type 1 : Epidemiology, pathophysiology, and treatment. Semin Nephrol 32 : 18-25, 2012
PubMed
4) Ronco C, Cicoira M, McCullough PA : Cardiorenal syndrome type 1. J Am Coll Cardiol 60 : 1031-1042, 2012
PubMed
5) Metra M, Davison B, Bettari L et al : Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5 : 54-62, 2012
PubMed
6) Thomas SS, Nohria A : Hemodynamic classification of acute heart failure and their clinical application-an update-Circ J 76 : 278-286, 2012
PubMed
7) Bellomo R, Giantomasso DD : Noradrenaline and the kidney : friends or foes. Critical Care 5 : 294-298, 2001
PubMed
8) Abuelo JG : Normotensive ischemic acute renal failure. N Engl J Med 357 : 797-805, 2007
PubMed
9) Hall JE, Guyton AC, Brands MW : Pressure-volume regulation in hypertension. Kidney Int (Suppl.) 55 : S35-S41, 1996
PubMed
10) Drazner MH, Hellkamp AS, Leier CV et al : Value of clinician assessment of hemodynamics in advanced heart failure : The ESCAPE trial. Circ Heart Fail 1 : 170-177, 2008
PubMed
11) Qureshi AI, Palesch YY, Martin R et al : Systolic blood pressure reduction and risk of acute renal injury in patients with intracerebral hemorrhage. Am J Med 125 : 718.e1-718.e6, 2012
 
12) Badin J, Boulain T, Ehrmann S et al : Relation between mean arterial pressure and renal function in the early phase of shock : a prospective, explorative cohort study. Crit Care 15 : R135, 2011
 
13) Thooft A, Favory R, Salgado DR et al : Effects of changes in arterial pressure on organ perfusion during septic shock. Crit Care 15 : R222, 2011
PubMed
14) Deruddre S, Cheisson G, Mazoit JX et al : Renal arterial resistance in septic shock : effects of increasing mean arterial pressure with norepinephrine on the renal resistive index assessed with Doppler ultrasonography. Intensive Care Med 33 : 1557-1562, 2007
PubMed
15) Nohria A, Hasselblad V, Stebbins A et al : Cardiorenal interactions : insights from the ESCAPE trial. J Am Coll Cardiol 51 : 1268-1274, 2008
 
16) Mullens W, Abrahams Z, Francis GS et al : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 : 589-596, 2009
PubMed
17) Mullens W, Abrahams Z, Skouri HN et al : Elevated intra-abdominal pressure in acute decompensated heart failure. J Am Coll Cardiol 51 : 300-306, 2008
PubMed
18) Sarraf M, Masoumi A, Schrier RW : Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 4 : 2013-2026, 2009
PubMed
19) Friedrich JO, Adhikari N, Herridge MS, Beyene J : Meta-analysis : low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142 : 510-524, 2005
 
20) De Backer D, Biston P, Devriendt J et al : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010
 
21) Dickstein K, Cohen-Solal A, Filippatos G et al : ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Euro J Heart Fail 933-989, 2008
 
22) Arnold JM, Howlett JG, Dorian P et al : Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007 : Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 23 : 21-45, 2007
PubMed
23) Sackner-Bernstein JD, Skopicki HA, Aaronson KD : Risk of worsening renal function with nesiritide in patient with acutely decompensated heart failure. Circulation 111 : 1487-1491, 2005
PubMed
24) Riter HG, Redfield MM, Burnett JC, Chen HH : Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 47 : 2334-2335, 2006
PubMed
25) O'Connor CM, Starling RC, Hernandez AF et al : Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 : 32-43, 2011
PubMed
26) Hata N, Seino Y, Tsutamoto T et al : Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure : the PROTECT multicenter randomized controlled study. Circ J 72 : 1787-1793, 2008
 
27) Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK : Atrial natriuretic peptide for management of acute kidney injury : a systematic review and meta-analysis. Clin J Am Soc Nephrol 4 : 261-272, 2009
PubMed
28) Shlipak MG : Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 138 : 917-924, 2003
PubMed
29) Yancy CW, Lopatin M, Stevenson LW et al : Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function : a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47 : 76-84, 2006
 
30) Nadeau-Fredette AC, Bouchard J : Fluid management and use of diuretics in acute kidney injury. Adv Chronic Kidney Dis 20 : 45-55, 2013
PubMed
31) Hasselblad V, Gattis Stough W, Shah MR et al : Relation between dose of loop diuretics and outcomes in a heart failure population : results of the ESCAPE trial. Eur J Heart Fail 9 : 1064-1069, 2007
 
32) Salvador DR, Rey NR, Ramos GC et al : Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005 ; 3 : CD003178.
PubMed
33) Felker GM, Lee KL, Bull DA et al : Diuretic strategy in patients with acute decompensated heart failure. N Engl J Med 364 : 797-805, 2011
PubMed
34) Gupta S, Neyses L : Diuretic usage in heart failure : a continuing conundrum in 2005. Eur Heart J 26 : 644-649, 2005
PubMed
35) Konstam MA, Gheorghiade M, Burnett JC Jr et al : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA 297 : 1319-1331, 2007
PubMed
36) Matue Y, Suzuki M, Seya M et al : Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61 (2) : 169-174, 2013
 
37) Bettari L, Fiuzat M, Felker GM, O'Connor CM : Significance of hyponatremia in heart failure. Heart Fail Rev 17 : 17-26, 2012
PubMed
38) Liszkowski M, Nohria A : Rubbing salt into wounds : hypertonic saline to assist with volume removal in heart failure. Curr Heart Fail Rep 7 : 134-139, 2010
PubMed
39) Boerrigter G, Costello-Boerrigter LC, Abraham WT et al : Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Cardiac Fail 14 : 539-546, 2008
PubMed
40) Konstam MA, Gheorghiade M, Burnett JC et al : Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Inbestigators : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : The EVEREST Outcome Trial. JAMA 297 : 1319-1343, 2007
PubMed
41) Bart BA, Goldsmith SR, Lee KL et al : Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 : 2296-2304, 2012
PubMed
P.240 掲載の参考文献
1) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 : 854-865, 1998
PubMed
2) Rao AD, Kuhadiya N, Reynolds K, Fonseca VA : Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? : a meta-analysis of observational studies. Diabetes Care 31 : 1672-1678, 2008
PubMed
3) Rosenstock J, Brown A, Fischer J et al : Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 21 : 2050-2055, 1998
PubMed
4) Inzucchi SE, Maggs DG, Spollett GR et al : Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338 : 867-872, 1998
PubMed
5) Hong J, Zhang Y, Lai S et al : Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. Diabetes Care 2012
 
6) Roussel R, Travert F, Pasquet B et al : Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170 : 1892-1899, 2010
PubMed
7) Bodmer M, Meier C, Krahenbuhl S et al : Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia : a nested case-control analysis. Diabetes Care 31 : 2086-2091, 2008
 
8) Salpeter SR, Greyber E, Pasternak GA, Salpeter EE : Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus : systematic review and meta-analysis. Arch Intern Med 163 : 2594-2602, 2003
PubMed
9) Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE : Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010 : CD002967
PubMed
10) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 : 837-853, 1998
 
11) Gerstein HC, Bosch J, Dagenais GR et al : Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 : 319-328, 2012
PubMed
12) Frye RL, August P, Brooks MM et al : A randomized trial of therapies for type 2 diabetes and coronary artery disease. The New England journal of medicine 360 : 2503-2515, 2009
PubMed
13) Schramm TK, Gislason GH, Vaag A et al : Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction : a nationwide study. Eur Heart J 32 : 1900-1908, 2011
PubMed
14) Holman RR, Paul SK, Bethel MA et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 : 1577-1589, 2008
PubMed
15) Holstein A, Plaschke A, Egberts EH : Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17 : 467-473, 2001
PubMed
16) Stratton IM, Adler AI, Neil HA et al : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. Bmj 321 : 405-412, 2000
PubMed
17) Gangji AS, Cukierman T, Gerstein HC et al : A systematic review and meta-analysis of hypoglycemia and cardiovascular events : a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30 : 389-394, 2007
PubMed
18) Kaku K, Daida H, Kashiwagi A et al : Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin 25 : 2925-2932, 2009
PubMed
19) Dormandy JA, Charbonnel B, Eckland DJ et al : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366 : 1279-1289, 2005
PubMed
20) Richter B, Bandeira-Echtler E, Bergerhoff K et al : Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006 : CD006060
 
21) Lincoff AM, Wolski K, Nicholls SJ, Nissen SE : Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus : a meta-analysis of randomized trials. JAMA 298 : 1180-1188, 2007
PubMed
22) Van de Laar FA, Lucassen PL, Akkermans RP et al : Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 : CD003639
PubMed
23) Aguilar D, Chan W, Bozkurt B et al : Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 4 : 53-58, 2011
PubMed
24) Turner RC, Millns H, Neil HA et al : Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus : United Kingdom Prospective Diabetes Study (UKPDS : 23). Bmj 316 : 823-828, 1998
PubMed
25) Finfer S, Chittock DR, Su SY et al : Intensive versus conventional glucose control in critically ill patients. The New England journal of medicine 360 : 1283-1297, 2009
 
26) Ismail-Beigi F : Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med 366 : 1319-1327, 2012
PubMed
P.248 掲載の参考文献
1) Hawkins NM, Petrie MC, Jhund PS et al : Heart failure and chronic obstructive pulmonary disease : diagnostic pitfalls and epidemiology. 2009
PubMed
2) Hawkins NM, Wang D, Petrie MC et al : Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 12 (6) : 557-565, 2010
PubMed
3) Wang CS, FitzGerald JM, Schulzer M et al : Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 294 (15) : 1944-1956, 2005
PubMed
4) McCullough PA : B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure : Analysis From Breathing Not Properly (BNP) Multinational Study. Circulation 106 (4) : 416-422, 2002
PubMed
5) Mueller C, Scholer A, Laule-Kilian K et al : Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea. N Engl J Med 350 : 647-654, 2004
PubMed
6) Lichtenstein DA : Relevance of Lung Ultrasound in the Diagnosis of Acute Respiratory Failure * : The BLUE Protocol. Chest 134 (1) : 117, 2008
PubMed
7) Prosen G, Klemen P, Strnad M, Grmec S : Combination of lung ultrasound (a comet-tail sign) and N-terminal probrain natriuretic peptide in differentiating acute heart failure from chronic obstructive pulmonary disease and asthma as cause of acute dyspnea in prehospital emergency setting. Critical Care 15 (2) : R114, 2011
 
8) Agricola E, Bove T, Oppizzi M et al : "Ultrasound comet-tail images" : a marker of pulmonary edema : a comparative study with wedge pressure and extravascular lung water. Chest 127 (5) : 1690-1695, 2005
PubMed
9) Frassi F, Gargani L, Gligorova S et al : Clinical and echocardiographic determinants of ultrasound lung comets. European Journal of Echocardiography 8 (6) : 474-479, 2007
PubMed
10) Volpicelli G, Caramello V, Cardinale L et al : Bedside ultrasound of the lung for the monitoring of acute decompensated heart failure. The American Journal of Emergency Medicine 26 (5) : 585-591, 2008
PubMed
11) Bateman ED, Rennard S, Barnes PJ et al : Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 22 (6) : 533-542, 2009
PubMed
12) Xamoterol in severe hart failure study group : xamoterol in severe heart failure. Lancent 336 : 1-6, 1990
 
13) The TORCH Study Group : The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal 24 (2) : 206-210, 2004
 
14) Singh S, Loke YK, Furberg CD : Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA 300 (12) : 1439-1450, 2008
PubMed
15) Oba Y, Zaza T, Thameem DM : Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 3 (4) : 575-584, 2008
PubMed
16) Vogelmeier C, Hederer B, Glaab T et al : Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364 (12) : 1093-1103, 2011
PubMed
17) Shawartz S et al : Life-thretening cold and exercise-induced asthma potentiated by administration of propranolol. Chest 78 : 100-101, 1980
 
18) Salpeter SR, Ormiston TM, Salpeter EE : Cardioselective beta-blockers in patients with reactive airway disease : a meta-analysis. Ann Intern Med 137 (9) : 715-725, 2002
PubMed
19) Fogari R, Zoppi A, Tettamanti F : Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 4 (4) : 1145-1149, 1990
PubMed
20) Salpeter SR, Ormiston TM, Salpeter EE : Cardioselective beta-blockers for chronic obstructive pulmonary disease : a meta-analysis. Respiratory Medicine 97 (10) : 1094-1101, 2003
PubMed
21) Jabbour A, Macdonald PS, Keogh AM et al : Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease : a randomized crossover trial. J Am Coll Cardiol 55 (17) : 1780-1787, 2010 doi : 1016/j.jacc.2010.01.024
 
22) Chen J, Radford MJ, Wang Y et al : Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 37 (7) : 1950-1956, 2001
PubMed
23) Angeloni E, Melina G, Roscitano A et al : beta-Blockers Improve Survival of Patients With Chronic Obstructive Pulmonary Disease After Coronary Artery Bypass Grafting. Ann Thorac Surg 95 : 525-531, 2013 doi : 10.1016/j.athoracsur.2012.07.080
 
24) Hawkins NM, Huang Z, Pieper KS et al : Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction : analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 11 (3) : 292-298, 2009
 
25) Short PM, Lipworth SIW, Elder DHJ et al : Effect of beta blockers in treatment of chronic obstructive pulmonary disease : a retrospective cohort study. BMJ 342 : d2549, 2011
PubMed
26) Etminan M, Jafari S, Carleton B, Fitzgerald JM : Beta-blocker use and COPD mortality : a systematic review and meta-analysis. BMC Pulm Med 12 : 48, 2012 doi : 10.1186/1471-2466-12-48
 
27) Abraham WT, Chin FMH, Feldman AM et al : ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 46 : e1-e82, 2005
 
28) Authors/Task Force Members, Dickstein K, Cohen-Solal A et al : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29 (19) : 2388-2442, 2008
 

書評

最近チェックした商品履歴

Loading...